ERBB2 and breast cancer: Trastuzumab (T) is a human epidermal growth factor receptor-2 (HER2) monoclonal antibody that, when paired with adjuvant chemotherapy, can reduce the recurrence rate of HER2-positive early breast cancer by 50% [36], of which the administration in combination with 1-year adjuvant Trastuzumab to the HER2-positive breast cancer women was shown, by a protocol-specified analysis on 3222 HER2-positive breast cancer patients, to have dramatically increased disease-free survival [37].